Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.34 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.31 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.31 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.31 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27794043 | 0.79 | THRB (0.39) | HPGDALDH1A1 | |
| SCHEMBL6079513 | 0.79 | GPR84 (0.31) | HPGDADRA1A | |
| SCHEMBL6079293 | 0.78 | CHRM1 (0.38) | HPGDADRA1ASLC1A3SLC1A2 | |
| SCHEMBL6330662 | 0.74 | FFAR1 (0.47) | ALDH1A1 | |
| SCHEMBL3933168 | 0.72 | GABRP (0.48) | SLC7A5HPGDALDH1A1 | |
| SCHEMBL3901922 | 0.70 | GABRP (0.50) | RNPEP | |
| SCHEMBL3763074 | 0.69 | NPC1 (0.36) | HPGDADRA1AALDH1A1 | |
| SCHEMBL3047422 | 0.69 | TSHR (0.36) | — | |
| SCHEMBL6328432 | 0.69 | HPGD (0.55) | HPGDADRA1A | |
| SCHEMBL6078263 | 0.68 | CETP (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6900243-B2 | Phenylheteroalkylamine derivatives | ASTRAZENECA AB (SE) | 2005-05-31 | — | — | US | disclosed |
| EP-1263715-B1 | NOVEL PHENYLHETEROALKYLAMINE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-04-28 | — | — | EP | disclosed |
| US-20030065174-A1 | Novel phenylheteroalkylamine derivatives | ASTRAZENECA AB (SE) | 2003-04-03 | — | — | US | disclosed |
| EP-1263715-A1 | NOVEL PHENYLHETEROALKYLAMINE DERIVATIVES | AstraZeneca AB (SE) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001062714-A1 | NOVEL PHENYLHETEROALKYLAMINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065174-A1 | Novel phenylheteroalkylamine derivatives | OPRK1, NOS2, OPRM1 | RNPEP 1206/4885SLC7A5 3051/4885HPGD 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.